Schiff Advises Underwriter in the Unicycive Therapeutics’ $25M IPO
Schiff Hardin LLP acted as underwriter’s counsel for Unicycive Therapeutics’ $25 million initial public offering.
Schiff Hardin LLP acted as underwriter’s counsel for Unicycive Therapeutics’ $25 million initial public offering. Unicycive is a clinical stage biotechnology company developing therapies for patients with kidney disease. The offering closed July 15, 2021.
Roth Capital Partners is acting as the sole manager for the offering.
Smart In Your World
Your goals define our mission. Whether an immediate need or a long-term objective, ArentFox Schiff helps you reach your full potential. As industry insiders, we partner with you to develop practical business strategies and sophisticated legal solutions to achieve today’s targets and anticipate tomorrow’s problems. We get you across the finish line.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Practices